Vanda Pharmaceuticals (VNDA) Net Cash Flow (2010 - 2026)

Vanda Pharmaceuticals has disclosed Net Cash Flow across 17 years of filings, most recently posting -$30.8 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$30.8 million, down 426.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$57.7 million (down 334.92% YoY), and the FY2025 annual result was -$17.5 million, up 47.55% from the prior year.
• Net Cash Flow came in at -$30.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $14.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $219.1 million in Q1 2023 to a low of -$204.1 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$8.8 million (2022), against an average of $105764.7.
• Across the five-year window, Net Cash Flow soared 5078.73% in 2022 and plunged 2224.23% in 2023, its largest moves.
• Vanda Pharmaceuticals' Net Cash Flow stood at $85.4 million in 2022, then slumped by 155.61% to -$47.5 million in 2023, then soared by 104.25% to $2.0 million in 2024, then surged by 632.76% to $14.8 million in 2025, then slumped by 307.71% to -$30.8 million in 2026.
• The last three Net Cash Flow figures came in at -$30.8 million (Q1 2026), $14.8 million (Q4 2025), and -$10.8 million (Q3 2025), per Business Quant data.